Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) CAO Sells $243,219.83 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CAO Patricia Carr sold 1,253 shares of the stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $194.11, for a total transaction of $243,219.83. Following the completion of the transaction, the chief accounting officer owned 10,352 shares in the company, valued at $2,009,426.72. The trade was a 10.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Patricia Carr also recently made the following trade(s):

• On Friday, February 27th, Patricia Carr sold 1,117 shares of Jazz Pharmaceuticals stock. The shares were sold at an average price of $190.91, for a total transaction of $213,246.47.
• On Friday, December 5th, Patricia Carr sold 4,660 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $171.20, for a total value of $797,792.00.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $188.69 on Thursday. The business’s fifty day moving average is $170.69 and its 200 day moving average is $153.18. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $198.00. The company has a debt-to-equity ratio of 1.00, a quick ratio of 1.67 and a current ratio of 1.86. The company has a market capitalization of $11.62 billion, a PE ratio of -31.61, a price-to-earnings-growth ratio of 0.37 and a beta of 0.22.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 EPS for the quarter, topping the consensus estimate of $6.49 by $0.15. The firm had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The business’s revenue for the quarter was up 8.1% compared to the same quarter last year. During the same quarter last year, the company earned $6.51 earnings per share. Sell-side analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on JAZZ shares. UBS Group reissued a “neutral” rating and issued a $188.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Monday, November 24th. Robert W. Baird raised their price target on Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a report on Tuesday, November 18th. Wall Street Zen upgraded Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Morgan Stanley increased their target price on Jazz Pharmaceuticals from $225.00 to $226.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Finally, Wells Fargo & Company lifted their target price on Jazz Pharmaceuticals from $235.00 to $250.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Fourteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $214.57.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. DGS Capital Management LLC purchased a new position in Jazz Pharmaceuticals during the 4th quarter valued at approximately $260,000. Pacer Advisors Inc. boosted its position in shares of Jazz Pharmaceuticals by 19.8% during the 4th quarter. Pacer Advisors Inc. now owns 647,084 shares of the specialty pharmaceutical company’s stock valued at $110,004,000 after acquiring an additional 107,144 shares during the last quarter. Kera Capital Partners Inc. purchased a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at $336,000. Dean Capital Management increased its position in Jazz Pharmaceuticals by 3.2% in the fourth quarter. Dean Capital Management now owns 21,158 shares of the specialty pharmaceutical company’s stock worth $3,597,000 after purchasing an additional 654 shares during the last quarter. Finally, Compound Planning Inc. purchased a new stake in Jazz Pharmaceuticals during the fourth quarter valued at $313,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.